Real-world effectiveness of imeglimin in patients with type 2 diabetes: A retrospective longitudinal study in Japan

IF 6.1 3区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes research and clinical practice Pub Date : 2024-07-01 DOI:10.1016/j.diabres.2024.111752

Hisayuki Katsuyama, Mariko Hakoshima, Takahiro Heshiki, Sakura Iida, Hiroki Adachi, Hidekatsu Yanai

{"title":"Real-world effectiveness of imeglimin in patients with type 2 diabetes: A retrospective longitudinal study in Japan","authors":"Hisayuki Katsuyama, Mariko Hakoshima, Takahiro Heshiki, Sakura Iida, Hiroki Adachi, Hidekatsu Yanai","doi":"10.1016/j.diabres.2024.111752","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To examine the real-world effects of imeglimin on glycemic control and other metabolic factors in patients with type 2 diabetes (T2DM).</p></div><div><h3>Methods</h3><p>A retrospective longitudinal study was conducted based on a chart review. We recruited patients with T2DM who took imeglimin continuously for at least 3 months. Data on various metabolic parameters were collected at the first prescription of imeglimin and at 3, 6 and 12 months after the initiation of imeglimin. Statistical comparisons were performed using paired t-tests.</p></div><div><h3>Results</h3><p>68 patients were eligible for this study. HbA1c decreased by 0.7 % at 3 months, 1.1 % at 6 months and 1.0 % by 12 months after the initiation of imeglimin. The decreases in HbA1c were observed regardless of age, gender, body mass index, duration of diabetes, renal function and concomitant use of hypoglycemic agents. There were also significant decreases in body weight, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) and non-HDL-C during imeglimin treatment.</p></div><div><h3>Conclusions</h3><p>This is the first report showing the long-term effects of imeglimin in a real-world setting. We confirmed the glucose-lowering effects of imeglimin. Furthermore, favorable effects of imeglimin on body weight and serum lipids were also suggested.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":null,"pages":null},"PeriodicalIF":6.1000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0168822724006624/pdfft?md5=f1e5dde379871264b6cdc4b38d5b3631&pid=1-s2.0-S0168822724006624-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168822724006624","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To examine the real-world effects of imeglimin on glycemic control and other metabolic factors in patients with type 2 diabetes (T2DM).

Methods

A retrospective longitudinal study was conducted based on a chart review. We recruited patients with T2DM who took imeglimin continuously for at least 3 months. Data on various metabolic parameters were collected at the first prescription of imeglimin and at 3, 6 and 12 months after the initiation of imeglimin. Statistical comparisons were performed using paired t-tests.

Results

68 patients were eligible for this study. HbA1c decreased by 0.7 % at 3 months, 1.1 % at 6 months and 1.0 % by 12 months after the initiation of imeglimin. The decreases in HbA1c were observed regardless of age, gender, body mass index, duration of diabetes, renal function and concomitant use of hypoglycemic agents. There were also significant decreases in body weight, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) and non-HDL-C during imeglimin treatment.

Conclusions

This is the first report showing the long-term effects of imeglimin in a real-world setting. We confirmed the glucose-lowering effects of imeglimin. Furthermore, favorable effects of imeglimin on body weight and serum lipids were also suggested.

查看原文本刊更多论文

伊迈格列明对 2 型糖尿病患者的实际疗效：日本的一项回顾性纵向研究。

目的研究伊迈格列明对 2 型糖尿病（T2DM）患者血糖控制和其他代谢因素的实际影响：方法：在病历回顾的基础上开展了一项回顾性纵向研究。我们招募了连续服用伊迈格列明至少 3 个月的 T2DM 患者。在首次开具伊迈格列明处方时以及开始服用伊迈格列明后的 3、6 和 12 个月收集了各种代谢参数的数据。统计比较采用配对 t 检验：68名患者符合研究条件。开始使用伊迈格列明后，3 个月时 HbA1c 下降了 0.7%，6 个月时下降了 1.1%，12 个月时下降了 1.0%。HbA1c 的下降与年龄、性别、体重指数、糖尿病病程、肾功能和同时使用的降糖药物无关。在伊麦格列明治疗期间，体重、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）和非高密度脂蛋白胆固醇也明显下降：这是第一份在真实世界环境中显示伊麦格列明长期疗效的报告。我们证实了伊麦格列明在实际临床环境中的降糖效果。此外，伊麦格列明还对体重和血清脂质产生了有利影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes research and clinical practice 医学-内分泌学与代谢

CiteScore

10.30

自引率

3.90%

发文量

862

审稿时长

32 days

期刊介绍： Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.

文献相关原料

公司名称	产品信息	采购帮参考价格